IGF-1 LR3 half-life and pharmacokinetics chart
Pre-filled plasma half-life model for IGF-1 LR3. See how a 25 hours half-life affects steady state, accumulation, peak-trough swing, and clearance timing.
Preset values: 40 mcg every 1 day, half-life ~25 hours.
LR3 modification extends half-life to ~20–30h. Daily dosing leads to moderate accumulation (~2×).
Open interactive chart →Why these values?
The half-life used here (25 hours) is the published or well-established estimate for IGF-1 LR3 from pharmacokinetic studies. The default dose (40 mcg) and cadence (every 1 day) reflect typical standard protocols — not a prescription or recommendation. Your specific product's label and your clinician's protocol override any default here.
Accumulation. With a half-life of 25 hours and dosing every 1 day, the ratio τ/t½ = 0.96 gives an accumulation factor of ~2.06×. That means the steady-state peak plasma mass is about 2.1× the mass of a single dose.
Time to steady state. Approximately 5 half-lives (~5.2 days) of consistent dosing before average concentration stops rising. Dose-escalation protocols that change doses before this point are titrating against a still-rising baseline, which is one reason weekly peptides feel "slow" at the start.
What the chart shows — and what it doesn't
The visualizer is a simple first-order single-compartment exponential decay model. It's accurate enough for understanding dosing rhythm, peak-trough ratios, and steady-state math, but not clinical pharmacokinetics. It doesn't model:
- Absorption delay from subcutaneous injection depots
- Two-compartment distribution (central vs peripheral)
- Protein binding (significant for GLP-1 agonists with albumin binding)
- Individual variability in clearance (renal, hepatic)
- Receptor-level effects that outlast plasma clearance
For most questions about "how often should I dose," the model is sufficient. For clinical decisions, use the manufacturer's label and a qualified prescriber.
IGF-1 LR3 half-life FAQ
What is the plasma half-life of IGF-1 LR3?
This chart uses an estimated IGF-1 LR3 plasma half-life of about 25 hours. Published values can vary by formulation, route, assay, and study design.
How long until IGF-1 LR3 reaches steady state?
A simple first-order model reaches practical steady state after about five half-lives, which is roughly 5.2 days for IGF-1 LR3.
Does this IGF-1 LR3 pharmacokinetics chart recommend a dosing schedule?
No. It visualizes half-life, accumulation, peaks, and troughs from values you enter. It is not a prescription, dose recommendation, or substitute for the product label or clinician guidance.
Why does steady state matter for IGF-1 LR3?
Steady state explains why long-half-life compounds can keep rising for weeks after starting or changing a dose, while short-half-life compounds behave more like brief pulses.
Related for IGF-1 LR3
Track your real IGF-1 LR3 protocol
Peptide Protocol logs every actual injection time and shows your real timeline — not a model. Side-effect tracking included.
Get the iPhone app →Educational use only. Nothing on this page constitutes medical advice. Pharmacokinetic parameters are published estimates; individual PK varies. Use label values and consult a clinician for any dosing decision.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.